Mindfulness-Enhanced Dual-Task Training in PD-MCI

Summary

The goal of this clinical trial is to learn if Mindfulness-Enhanced Dual-Task Training work to treat PD-MCI in adults. The main questions it aims to answer are: Does Mindfulness-Enhanced Dual-Task Training improve the cognitive or motor function of participants? Can the combination of Dual-Task Training and Mindfulness achieve better effects? Researchers will compare 3 groups (Dual-Task Training + Mindfulness, Dual-Task Training, and conventional motor task training) to see if Dual-Task Training and Mindfulness works to treat PD-MCI. Participants will: Receive treatment for 4 weeks Receive scale and instrument testing before and after treatment

Interventions

• Cognitive-Motor Dual-Task Training · DEVICE

  Participants perform physical exercises using the balance training system and isokinetic muscle strength training system while simultaneously completing cognitive tasks to improve motor-cognitive coordination. The training follows a task-segmentation approach: Balance Task Module: Participants perform dynamic balance training on the balance training system while engaging in cognitive tasks (e.g., digit span, arithmetic, or word fluency tasks). Strength Task Module: Participants conduct isokinetic strength training while performing corresponding cognitive tasks. Task difficulty is progressively adjusted based on participant performance.

• Mindfulness Training · OTHER

  Guided by a professional mindfulness instructor, participants engage in mindfulness meditation to enhance attention, emotional regulation, and cognitive readiness. The training includes breath awareness, body scan, and present-moment awareness, delivered through guided meditation.

• Single-task Training · DEVICE

  Participants perform physical exercises using the balance training system and isokinetic muscle strength training system without any concurrent cognitive tasks. The training follows a task-segmentation approach, including dynamic balance training and isokinetic strength training to enhance motor function.

• Quiet Rest · OTHER

  Participants remain seated in a quiet environment without engaging in mindfulness training or cognitive tasks.

Published eligibility criteria

Verbatim from the registry. Only the site can decide how these apply to a specific patient.

Inclusion Criteria:

* Age: Between 55 and 75 years.
* Disease Diagnosis: Clinically diagnosed with Idiopathic Parkinson's Disease (PD) according to the UK Parkinson's Disease Society Brain Bank Criteria.
* Disease Stage: Hoehn \& Yahr (H\&Y) stages 1 to 2.5.
* Cognitive Function: Montreal Cognitive Assessment (MoCA) score between 23 and 26, indicating mild cognitive impairment (MCI).
* Medication Stability: Stable doses of antiparkinsonian medications for at least 4 weeks prior to screening.
* Subjective Cognitive Complaints: Self-reported or informant-reported cognitive decline persisting for at least 6 months.
* Ambulatory Ability: Able to walk independently, with or without assistive devices.
* Sensory Abilities: Adequate vision and hearing to comply with study procedures.
* Informed Consent: Willingness to provide written informed consent and comply with study requirements.

Exclusion Criteria:

* Other Neurological Disorders: Presence of other neurological conditions that could affect cognitive function, such as Alzheimer's disease, stroke, or brain tumors.
* Psychiatric Conditions: Severe psychiatric disorders, including major depressive disorder or schizophrenia.
* Substance Abuse: Recent history of drug or alcohol abuse.
* Serious Medical Conditions: Uncontrolled hypertension, diabetes, heart disease, or other conditions that could interfere with study participation or outcomes.
* Severe Cognitive Impairment: Diagnosis of Parkinson's Disease Dementia (PDD).
* Other Factors Affecting Cognition: Recent head trauma, uncontrolled thyroid dysfunction, vitamin B12 deficiency, or other conditions known to affect cognitive function.
* Deep Brain Stimulation (DBS): History of DBS treatment. Participation in Other Clinical Trials: Participation in another clinical trial that could interfere with this study within the last 3 months.

Sites (1)

• Nanjing Mingzhou Rehabilitation Hospital, Nanjing, Jiangsu, China